MRD positive acute myeloid leukemia
Conditions
Interventions
Experiment group:Sorafenib combined with venetoclax
Sponsors
Nanfang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Signed informed consent voluntarily; 2.Age>= 18; 3.Liver and kidney functions: blood bilirubin = 50%, New York Heart Function Classification NYHA I/II); 5.ECOG score: Physical condition score 0-2; 6.Non pregnant and lactating women; 7.For all women of childbearing age, hCG must be measured by pregnancy test to exclude pregnancy status; 8.For all men of childbearing age, contraceptive measures must be taken during sorafenib treatment until 3 months after withdrawal.
Exclusion criteria
Exclusion criteria: 1.Acute promyelocytic leukemia; 2.Non-response or relpase; 3.Uncontrolled infection or grade 3-4 graft-versus-host diseas; 4.Allergy or contraindication to any drug involved in the protocol (including sorafenib); 5.Severe heart, liver, kidney, lung and other organ dysfunction; 6.PLT lower than 20g/l, neu lower than 0.5g/l.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete molecular remission rate after 3 treatment courses;Death related to adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Event free of survival;Cumulative incidence of relapse;MRD negativity;Response rate of MRD;Overall survival; | — |
Countries
China
Contacts
Public ContactLiu Hui
Nanfang Hospital, Southern Medical University
Outcome results
None listed